Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes

Authors

• Gregory J. Grosicki, Medifast, Inc., Baltimore, MA
• J Graham Thomas, The Miriam Hospital, Providence, RI
• Nikhil V. Dhurandhar, Texas Tech University, Lubbock, TX
• Holly Lofton, New York University Grossman School of Medicine, New York, NY
• Steven B. Heymsfield, Pennington Biomedical Research Center, Baton Rouge, LA
• Satya S. Jonnalagadda, Medifast, Inc., Baltimore, MA

Document Type

Article

Publication Date

1-2-2025

Publication Title

Diabetes, Obesity and Metabolism

First Page

1597

Last Page

1600

DOI

10.1111/dom.16151

Rights

© 2025 John Wiley & Sons Ltd.

Recommended Citation

Grosicki, Gregory J.; Thomas, J Graham; Dhurandhar, Nikhil V.; Lofton, Holly; Heymsfield, Steven B.; and Jonnalagadda, Satya S., "Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes" (2025). LSU-LCMC Cancer Center Faculty Publications. 113.
https://digitalscholar.lsuhsc.edu/llcc_facpubs/113
10.1111/dom.16151